Gastrointestinal Cancer News

In a video exclusive, Paul Limburg, MD, Mayo Clinic, told Healio adherence rates for stool-based colorectal cancer screening and colonoscopy informed comparative effectiveness and the need for improved screening and follow-up adherence.

In this video exclusive, Roi Anteby, MD, postdoctoral research fellow, department of surgery, Massachusetts General Hospital, discussed the affect of race, socioeconomic status and education on completion of adjuvant therapy for pancreatic cancer.

The COVID-19 pandemic disrupted colorectal cancer screening programs around the world.

Screening endoscopy among otherwise healthy individuals aged older than 75 years appeared to lower the risk for colorectal cancer incidence and cancer-associated mortality, according to study results published in JAMA Oncology.

Colorectal cancer incidence and mortality decreased after implementation of a national fecal immunochemical test-based screening program in the Netherlands, according to research presented at Digestive Disease Week.

When given a choice, participants preferred fecal immunochemical test-based screening for colorectal cancer compared with a blood test, according to research presented at Digestive Disease Week.

The combination of fecal immunochemical test-based colonoscopy and fecal calprotectin detected advanced colorectal neoplasia, according to a presentation at Digestive Disease Week.

For years, standard treatment for patients with stage III colon cancer has been adjuvant chemotherapy for 6 months following resection.

Established in 1992 in response to the HIV epidemic, the FDA’s accelerated approval program offers a valuable opportunity to make potentially lifesaving therapeutics available to patients in a timely manner.

Incidence of cervical cancer declined as rates of other HPV-associated cancers increased significantly in the U.S. from 2001 to 2017, according to a population-based study of trends presented during the virtual ASCO Annual Meeting.